BioCentury
ARTICLE | Financial News

NaPro pops on paclitaxel approval

May 9, 2002 7:00 AM UTC

NPRO was up $2.44 (45%) to $7.92 on 4.4 million shares on Thursday. On Wednesday after market close, NPRO said the FDA approved its generic paclitaxel formulation to treat cancer (see BioCentury Extr...